NDAORALSOLUTIONPriority Review
Approved
Apr 2019
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
18
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORLANOR (ivabradine) is an oral small-molecule heart rate reducer approved by FDA in April 2019 for treating heart failure patients. It works by selectively inhibiting the If (funny) current in the sinoatrial node, lowering heart rate without negative inotropic effects. The drug is indicated for chronic heart failure patients with reduced ejection fraction who require heart rate control.
LOE Approaching6mo to LOE
With only 6 months until loss of exclusivity and moderate competitive pressure (25 rating), the brand team is likely in defense mode focusing on managed care relationships and patient retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
Started Jul 2022
200 enrolled
Heart FailureCardiogenic ShockIschemic Heart Disease
An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
Started Nov 2018
0Heart Transplantation, Elevated Resting Heart Rate
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
Started Jul 2018
19 enrolled
Heart Failure
Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
Started Mar 2018
40 enrolled
Heart FailureCardiogenic ShockTachycardia
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Started Feb 2018
23 enrolled
LymphomaAutonomic ImbalanceCancer Survivorship
Worked on CORLANOR at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.